Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
SK bioscience, a South Korean pharmaceutical firm, announced on Thursday, March 21, that it has exported its influenza vaccine to Thailand. The company developed a cell-cultured influenza vaccine, and after securing the required approvals and permits, it started exporting its Sky Cellflu to the country.
First Batch of Deliveries
According to The Korea Herald, SK Bioscience has already completed the first delivery, which consists of 440,000 doses of the Sky Cellflu vaccine. The products were handed over to its local partner, Biogenetech.
The Korean pharmaceutical company expects to receive more orders and expand its sales once the new influenza vaccine is distributed in Thailand. The deal also marks SK Bioscience's expansion in the Southeast Asian market and entry into the Southern space.
Timely Arrival of the Flu Vaccines
Korea IT Times reported that Thailand has been affected by flu strains, and vaccination is being sought to prevent infections. SK bioscience's Sky Cellflu was also approved by the World Health Organization (WHO) for use in the country.
Moreover, this export is expected to become an excellent example of proper vaccination to combat influenza. Meanwhile, Sky Cellflu already secured proper licenses for distribution in 12 countries, including Malaysia, Thailand, Chile, Singapore, Mongolia, and Pakistan.
World's First Cell Culture-Based Flu Vaccine
SK bioscience's SKYCellflu is said to be the first cell culture-based influenza vaccine in the world. It obtained WHO Pre-qualification (PQ) certification for safe usage and dissemination worldwide.
"The export of SKYCellflu to Thailand serves as a stepping-stone for entering the Southeast Asian and Southern Hemisphere markets and expanding into the global market," SK bioscience's chief executive officer, Ahn Jae Yong, said in a press release. "In addition to diversifying our existing product markets, we are committed to developing vaccines with blockbuster potential, such as our next-generation pneumococcal conjugate vaccine candidate, which is expected to enter phase III clinical trials this year."
Photo by: SK Bioscience Press Release
